anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention relates to a novel method of targeting biologically-active compounds to cells and organelles within cells. Specifically, the method comprises covalently linking such biologically-active compounds to a polar lipid carrier. The invention provides compositions of matter comprising such biologically-active compounds covalently linked to polar lipid carrier molecules that have the unique ability to both enhance the rate at which such biologically-active compounds cross cellular plasma membranes and to direct the compounds-lipid conjugate to specific organelles within the cell. The versatility of these conjugates may be further enhanced by including a spacer group between the drug and the lipid which may act to modulate release of the biologically-active compound at the target site. Specific embodiments of the compositions of the invention include antineoplastic and antiviral drugs. Other embodiments are provided for delivering and specific targeting of antigenically-active peptides to cells for the specific production of immunological reactivity against such peptides, as well ass compositions and pharmaceutical compositions of matter comprising such peptides. These embodiments of the invention thereby provide improved methods for vaccine production and in vivo vaccination against pathogenic microorganisms and methods for alleviating autoimmune disease and ameliorating tissue and organ transplant rejection.
The treatment of Mycobacterium avium complex (MAC) lung disease consists of best supportive care, often accompanied by long-lasting multi-drug antibiotic regimens. Two major radiologic patterns exist: nodular-bronchiectatic and fibrocavitary disease, characterized by slow and rapid progression of disease, respectively.

SALINE is an open-label, randomized, two-arm controlled study that investigates the effect of Hypertonic Saline inhalation (HSi) plus best supportive care versus best supportive care alone for 12 weeks in participants with nodular-bronchiectatic MAC lung disease. The investigators hypothesize that HSi added to best supportive care will improve health-related quality of life and reduce mycobacterial load more than best supportive care alone Participants will be randomized 1:1 to a study arm. Best supportive care comprises of management of a predisposing (lung) condition, guidance in smoking cessation, respiratory physiotherapy (e.g. airway clearance) and nutritional guidance. HSi will be administered two times daily. Antibacterial therapy against other bacterial infections and inhaled corticosteroids are allowed during the study period.
An extracellular vesicle-containing sample can be processed using a device for isolating one or more subpopulations of the extracellular vesicles. The extracellular vesicle-containing sample is flowed through a flow chamber of the device under an applied fluid pressure, in which the device has one or more inlets and two or more outlets in fluid communication with one another via the flow chamber. The device has one or more filters in the flow chamber between the inlet(s) and at least one of the outlet(s). The extracellular vesicle-containing sample is flowed through the filter(s) in the flow chamber to sort the extracellular vesicles of extracellular vesicle-containing sample by size into two or more subpopulations of the extracellular vesicles. At least one of the subpopulations that has been sorted flows out of a corresponding one of the outlets. Surface marker-based exosome sorting using magnetic beads may be used after the size-based exosome isolation.
The N-of-1 trial will, on the level of the individual patient, test whether open-label placebo reduces negative side effects caused by discontinuation of antidepressants compared to no treatment. After antidepressant discontinuation, subjects will be randomized to 2 arms differing in the treatment order (ABAB; BABA). Subjects in this arm (ABAB) will start with open-label placebo (A) for 2 weeks; they will then crossover to no treatment (B) for 2 weeks and repeat this sequence once again.
Recruited cancer patients/survivors will be asked to beta-test the cancer-specific app prototype for four weeks. The prototype will be developed in Aim 2 and informed by qualitative findings of Aim 1.
The escalation of global obesity is driving research to understand environmental influences on this process, particularly during vulnerable developmental stages such as childhood and adolescence. Efforts include the development of various structured data collection tools. We aimed to adapt a series of previously validated questionnaires from the International Study of Childhood Obesity, Lifestyle and the Environment (ISCOLE), the Child Feeding Questionnaire, and elements from the World Health Organization Childhood Obesity Surveillance Initiative (COSI) in order to assess local lifestyle patterns among Romanian high school students and their families that may predispose them to obesity. To this goal, an expert committee was formed as part of a research partnership to oversee the questionnaire's translation and adaptation. It consisted of education and school management specialists, clinical research professionals, language experts, and public health experts. The adapted questionnaires were then applied to 114 students enrolled in the 9th and 10th grades attending a high school situated in Sibiu, and their parents. The variables measured were investigated for correlations with overweight and obesity and, as a secondary objective, academic performance. The study revealed several critical findings, including suboptimal sleep durations and physical activity levels among students, a significant amount of screen time, and correlations between weight status and physical activity, sedentary time, and maternal weight status and education levels. The adapted questionnaires proved to be effective tools in capturing the multifaceted factors implicated in adolescent obesity, providing a foundation for targeted interventions and broader public health strategies to address this issue.
Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative. 

Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.1 times the highest recommended adult human dose based on mg/m 2) revealed no effects on fertility or mating ability. 

Pregnancy: Teratogenic effects 

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities. 

Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed. 

Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (2.1 and 1.1 times the highest recommended adult human dose based on mg/m 2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (0.9 and 0.5 times the highest recommended adult human dose based on mg/m 2, respectively) revealed no evidence of teratogenicity. 

Clindamycin injection contains benzyl alcohol. Benzyl alcohol can cross the placenta. See WARNINGS.
PURPOSE:To provide a remedy for hepatitis containing ethyl gallate as an active component and exhibiting protective effect to hepatic disorder of an experimental hepatic disorder model caused by galactosamine by oral administration. CONSTITUTION:Ethyl gallate is used as a remedy for hepatitis. Ethyl gallate is rich in fresh leaves of Bixa orellana L. (a plantnative to Indonesia) and an extract of the leaf may be used as the agent. Concretely, fresh leaves of Bixa orellana L. are immersed in 50% ethanol, the solvent is distilled off under reduced pressure, the residue is extracted with ethyl acetate and the solvent is distilled off. The residue is subjected to silica gel column chromatography and eluted with a chloroform-methanol mixture (10:1 V/V) to obtain ethyl gallate. It exhibits protective effect to hepatic disorder by oral administration.
What is disclosed is a system and method for forecasting and imputing an unknown vital measurement of a patient. Temporally successive patient vital measurements are received which comprise irregularly sampled observations {y1, . . . , yN}, where yj denotes the jth observation at time tj, and N is the number of samples. The vital measurements are then provided to a model trained using historical data of patient vital measurements. The model generates a parameter set θ=(A,B,C), where A is a state transition matrix, B is a control matrix, and C is a matrix which maps state-space variables to observation variables. The parameters are used to obtain state-space variable zt which, in turn, is used to forecast an unknown observation yN+1 or to impute an unknown observation yt, where 1<t<N. The historical data is then updated with the forecasted observation yN+1 or the imputed unknown observation yt.
The invention discloses a life sustaining agent for waterless low-temperature caught sea crab life sustaining. The life sustaining agent comprises, by mass, 5-10% of magnesium sulfate, 1.5-3.5% of potassium chloride, 2.5-6.5% of gypsum, 7.5-15% of rosmarinic acid, 0.0025-0.0065% of aldosterone and the balance water. The life sustaining agent has a scientific and reasonable formula and a low cost. Through cooperation of ingredients, caught sea crab survival time is prolonged, a caught sea crab survival rate is improved and a caught sea crab economic value is further improved. The invention also discloses a preparation method of the life sustaining agent for waterless low-temperature caught sea crab life sustaining. The preparation method realizes direct mixing of ingredients, has simple processes, high operationality, low equipment requirement and less investment and is suitable for industrial production.
The invention discloses a partially elastic shaped body in the form of a negative image of a dental arch containing a matrix based on a gel containing an active substance or a system with a mineralizing effect as well as an application system for the treatment of teeth. The application system comprises an application dental splint that is well-suited for use on the upper and/or lower jaw, whereby the dental splint can accommodate at least one first three-dimensional shaped body that is adapted to the splint and contains a matrix, preferably the dental splint can be deformed by heat. The matrix of the at least one first and optionally further shaped body contains at least one active substance or a system with a mineralizing effect containing phosphates, calcium, and fluorides. The method for producing the application system and a kit comprising the application system are also a subject matter of the invention. According to the invention, the application system and kit are used for depositing apatite, in particular needle-shaped fluorapatite crystals. According to the invention, it is feasible to deposit more than or equal to 1 μm apatite, in particular fluorapatite, on tooth surfaces over one sleeping period or during the day in order to seal or brighten porous tooth surfaces.
Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
PURPOSE:To provide the titled fine powder composed of regenerated protein fine powder containing an oily material dispersed and occluded therein as minute liquid droplets, containing an oily material having high functionality at a high rate, having excellent adhesivity, spreadability, masking power, dispersibility, etc., and useful for cosmetic, food, paint, etc. CONSTITUTION:An aqueous solution of a regenerated protein (e.g. silk fibroin, casein, collagen, etc.) having a concentration of 2-20(wt)%, especially 5-10% is mixed with an oily material or an oily material and an extender pigment and the resultant emulsified suspension liquid is subjected to isoelectric point coagulation, mixing with protein coagulant or agitation at high rate of shear strain (>=50sec<-1>, especially >=100sec<-1>) or their combination. The regenerated protein coagulated and precipitated by this procedure is washed with water, dried and pulverized to obtain the objective regenerated protein fine powder (preferably having maximum particle diameter of 3-30mu) containing an oily material and optionally an extender pigment dispersed and included in the powder as minute liquid droplets. The amount of the oily material included in the powder is 0.5-50%, preferably 1-20% of the powder and <=25 times, especially <=10 times weight of the regenerated protein.
###  Usual Initial Dosage

PAXIL CR should be administered as a single daily dose, usually in the morning, with or without food. PAXIL CR may be administered either daily throughout the menstrual cycle or limited to the luteal phase of the menstrual cycle, depending on physician assessment. The recommended initial dose is 12.5 mg/day. In clinical trials, both 12.5 mg/day and 25 mg/day were shown to be effective. Dose changes should occur at intervals of at least 1 week. 

Patients should be cautioned that PAXIL CR should not be chewed or crushed, and should be swallowed whole. 

###  Maintenance/Continuation Therapy

The effectiveness of PAXIL CR for a period exceeding 3 menstrual cycles has not been systematically evaluated in controlled trials. However, women commonly report that symptoms worsen with age until relieved by the onset of menopause. Therefore, it is reasonable to consider continuation of a responding patient. Patients should be periodically reassessed to determine the need for continued treatment.
FLOVENT DISKUS 100 mcg is supplied as a disposable orange plastic inhaler containing a foil blister strip with 60 blisters. The inhaler is packaged in a plastic-coated, moisture-protective foil pouch (NDC 63187-957-60). 

Store at room temperature between 68°F and 77°F (20°C and 25°C); excursions permitted from 59°F to 86°F (15°C to 30°C) [See USP Controlled Room Temperature]. Store in a dry place away from direct heat or sunlight. Keep out of reach of children. 

FLOVENT DISKUS should be stored inside the unopened moisture-protective foil pouch and only removed from the pouch immediately before initial use. Discard FLOVENT DISKUS 6 weeks (50-mcg strength) or 2 months (100- and 250-mcg strengths) after opening the foil pouch or when the counter reads “0” (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.
Patients Not Currently Receiving Octreotide Acetate

Patients not currently receiving octreotide acetate should begin therapy with octreotide acetate injection given subcutaneously. The suggested daily dosage for carcinoid tumors during the first 2 weeks of therapy ranges from 100 mcg/day to 600 mcg/day in 2 to 4 divided doses (mean daily dosage is 300 mcg). Some patients may require doses up to 1,500 mcg/day. The suggested daily dosage for VIPomas is 200 mcg to 300 mcg in 2 to 4 divided doses (range, 150 mcg to 750 mcg); dosage may be adjusted on an individual basis to control symptoms but usually doses above 450 mcg/day are not required.

Octreotide acetate injection should be continued for at least 2 weeks. Thereafter, patients who are considered “responders” to octreotide acetate, and who tolerate the drug, may be switched to octreotide acetate for injectable suspension in the dosage regimen as described below (Patients Currently Receiving Octreotide Acetate Injection).

Patients Currently Receiving Octreotide Acetate Injection

Patients currently receiving octreotide acetate injection can be switched to octreotide acetate for injectable suspension in a dosage of 20 mg given IM intragluteally at 4-week intervals for 2 months. Because of the need for serum octreotide to reach therapeutically effective levels following initial injection of octreotide acetate for injectable suspension, carcinoid tumor and VIPoma patients should continue to receive octreotide acetate injection subcutaneously for at least 2 weeks in the same dosage they were taking before the switch. Failure to continue subcutaneous injections for this period may result in exacerbation of symptoms (some patients may require 3 or 4 weeks of such therapy).

After 2 months, dosage may be adjusted as follows:

  * If symptoms are adequately controlled, consider a dose reduction to 10 mg for a trial period. If symptoms recur, dosage should then be increased to 20 mg every 4 weeks. Many patients can, however, be satisfactorily maintained at a 10-mg dose every 4 weeks.
  * If symptoms are not adequately controlled, increase octreotide acetate for injectable suspension to 30 mg every 4 weeks. Patients who achieve good control on a 20-mg dose may have their dose lowered to 10 mg for a trial period. If symptoms recur, dosage should then be increased to 20 mg every 4 weeks.
  * Dosages higher than 30 mg are not recommended.



Despite good overall control of symptoms, patients with carcinoid tumors and VIPomas often experience periodic exacerbation of symptoms (regardless of whether they are being maintained on octreotide acetate injection or octreotide acetate for injectable suspension). During these periods, they may be given octreotide acetate injection subcutaneously for a few days at the dosage they were receiving prior to switching to octreotide acetate for injectable suspension. When symptoms are again controlled, the octreotide acetate injection subcutaneous can be discontinued.
The disclosed method is directed to the use of highly selective PPARϜ inhibitors and to siRNA specific for PPARϜ for treating a patient suffering from a disease or condition characterize by excessive cell proliferation. Exemplary cancers treatable by the method of the invention include, but are not limited to, epithelial cell tumors of the lung, liver, colon, breast or prostate such as human colorectal carcinoma and hepatocellular carcinoma; and lymphocyte-based cancers such as leukemia, lymphoma and multiple myeloma. The method of the invention would be particularly useful for prevention of metastasis, e.g., of epithelial cell tumors, and for reduction in the size of primary tumors or reduction of the rate of proliferation of abnormal lymphocytes or the rate of growth of epithelial precancerous lesions, such as colon cancer polyps. The method of the invention would also be useful for treating diseases characterized by excessive tissue growth such as scleroderma, systemic sclerosis, amyloidosis and gastrointestinal stromal tumors. This treatment could also be used as an immunosuppressant, for preventing the proliferation of lymphocytes. Preferred PPARϜ inhibitors useful in the method of the invention are those that covalently bond to PPARϜ and modify its activity, e.g., by reaction of a nitrogen group in the inhibitor with a cysteine residue in the PPARϜ binding pocket.
Amboxol arm will be receiving "standard therapy" as per control group with the addition of IV ambroxol hydrochloride 30mg TDS as adjunct therapy for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour. The patients will be considered as drop-outs if ambroxol is discontinued due to its side-effects, or if the patient's duration of ICU stay is less than 24 hours.
A recombinant DNA molecule coding for a protein expressed by a Staphylococcus aureus bacterium, comprising the nucleotide sequence SEQ ID NO: 1 or a homologous sequence, or a partial or homologous sequence of SEQ ID NO: 1 coding for a polypeptide fragment comprising at least 15 amino acid residues, is described. Further, a protein expressed by such a bacterium or a polypeptide fragment comprising at least 15 amino acid residues, comprising the amino acid sequence SEQ ID NO: 2 binds IgG and apolipoprotein H. Examples of the polypeptide fragments comprise the SEQ ID NO: 3 through 6. These proteins and polypeptide fragments may be coupled to an inert carrier or matrix. Vectors comprising such a DNA molecule or the corresponding RNA molecule, and antibodies specifically binding to a polypeptide having an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, are also disclosed. The DNA or RNA molecules, the vectors and the antibodies mentioned may all be used in different types of vaccines against Staphylococcal infections. Moreover, a method of isolating and/or purifying apoliprotein H from a liquid medium, especially from serum, is described.
INTRODUCTION: We report a case of accelerated idioventricular rhythm (AIVR) identified by Emergency Medical Services (EMS) monitoring of an infant presenting with lethargy and respiratory distress. Accelerated idioventricular rhythms are rare ventricular rhythms originating from the His-Purkinje system or ventricular myocytes, consisting of >3 monomorphic beats with gradual onset and termination.1 An AIVR is usually well-tolerated and does not require treatment, though sustained arrythmia may induce syncope, and the rhythm has been seen in newborn infants with congenital heart diseases.1 Monitoring ill children with ECG can identify such dysrhythmias in the prehospital setting.
CASE REPORT: An 18-month-old male presented to their pediatrician with lethargy and respiratory distress, prompting activation of EMS. The patient was placed on a 4-lead ECG initially revealing monomorphic QRS complexes at a rate of 170 beats per minute (BPM). A 12-lead ECG was interpreted as sinus tachycardia by the paramedics who noted the QRS complexes were "getting taller and shorter" with a stable rapid heart rate. The clinician then noted a consistently wide tachycardia which spontaneously converted to a narrow complex tachycardia. The QRS pattern remained variable, with notation of variable R-wave height. After arrival to the emergency department, pediatric cardiology was consulted and interpreted the prehospital ECG findings as accelerated idioventricular rhythm. The patient experienced multiple occurrences of accelerated idioventricular rhythm during hospitalization without associated hypoxia or decreased perfusion.
DISCUSSION: Accelerated idioventricular rhythm is relatively rare entity without underlying cardiac disease and most cases are asymptomatic or benign. In the pediatric population, AIVR is generally related to congenital heart defects, cardiac tumors, and cardiomyopathies. In the prehospital setting, continuous ECG monitoring should be a part of care by Advanced Life Support personnel in children with altered mental status, respiratory distress, unexplained syncope, or suspected arrhythmias and 12 lead ECG should be considered if there is any abnormality noted. While this patient did not experience persisting morbidity from AIVR, the potentially hazardous rhythm would not have been recognized without the astute observation, clinical management and persistent follow up of the prehospital clinicians.